Oculis to Present at Goldman Sachs Conference

Oculis, a global biopharmaceutical company, announced its management's participation in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference on June 9, 2026, in Miami, FL. Dr. Riad Sherif, CEO of Oculis, will present an overview and update of the company's late-stage portfolio. Key highlights include Privosegtor, a neuroprotective candidate that received Breakthrough Therapy designation from the United States — Food and Drug Administration and Priority Medicines (PRIME) designation from the European Union — European Medicines Agency for optic neuritis, with a potential market opportunity of over $7 billion in the U.S. alone. Also featured is Licaminlimab, a topical anti-TNFa in a registrational trial for dry eye disease. Oculis aims to deliver several pivotal readouts with its current funding, focusing on its mission to improve eye care.